The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches

Abstract

Background WISDOM (Women Informed to Screen Depending on Measures of Risk) is a randomized trial to assess whether personalized breast cancer screening—where women are screened biannually, annually, biennially, or not at all depending on risk and age—can prevent as many advanced (stage IIB or higher) cancers as annual screening in women ages 40–74 years across 5 years of trial time. The short study time in combination with design choices of not requiring study entry and exit mammograms for all participants may introduce different sources of bias in favor of either the personalized or the annual arm. Methods We designed a simulation model and performed 5000 virtual WISDOM trials to assess potential biases. Each virtual trial simulated 65 000 randomly assigned participants who were each assigned a risk stratum and a time to stage of at least IIB cancer sampled from an exponential distribution with the hazard rate based on the risk stratum. Results from the virtual trials were used to evaluate two candidate analysis strategies with respect to susceptibility for introducing bias: 1) difference between arms in total number of events over total trial time, and 2) difference in number of events within complete screening cycles. Results Based on the simulations, about 86 stage IIB or higher cancers will be detected within the trial and the total exposure time will be about 74 000 years in each arm. Potential ascertainment bias is introduced at study entry and exit. Analysis strategy 1 works better for the nonscreened stratum, whereas method 2 is considerably more unbiased for the strata of women screened biennially or every 6 months. Conclusion Combining the two candidate analysis approaches gives a reasonably unbiased analysis based on the simulations and is the method we will use for the primary analysis in WISDOM. Publishing the WISDOM analysis approach provides transparency and can aid the design and analysis of other individualized screening trials.

European polygenic risk score for prediction of breast cancer shows similar performance in Asian women

“…In particular, using the recent extension of the BOADICEA model, it has been demonstrated that the 313-SNP PRS provides greater level of risk stratification in the population than epidemiological risk factors alone, and that the greatest level of risk stratification is achieved when both the PRS and epidemiological risk factors are considered jointly 10 . Screening trials 11 – 13 in women of predominantly European descent are ongoing to evaluate personalised breast cancer screening programme based on a woman’s individual risk of disease, as a means of improving screening efficiency 14 .…”

Comparison of breast density assessment between human eye and automated software on digital and synthetic mammography: Impact on breast cancer risk

“…Mammographers' acceptance of MammoRisk® for evaluating BC risk in the clinical setting is high [42] and the model is being increasingly used with training as part of the ambitious European clinical trial MyPeBS [29]. The primary objective of the MyPeBS study is the same as that of the WISDOM study conducted in the United States [43]: to evaluate the impact of personalized BC screening on the rate of diagnosis of BC stage 2B in the general population.…”

Machine learning-based lifetime breast cancer risk reclassification compared with the BOADICEA model: impact on screening recommendations

“…A prospective clinical trial would provide more functional and extended evaluation of the performance of ML algorithms, and findings can be compared with ongoing personalised breast cancer screening trials like 'My PeBS' and 'WISDOM'. 54,55…”